Piflufolastat F18 for Breast Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
MD Anderson Cancer Center, Houston, TX
Breast Cancer+7 More
Piflufolastat F18 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

To learn if piflufolastat F18 can be used in imaging scans for patients with breast cancer, HCC, or pancreatic cancer

Eligible Conditions

  • Breast Cancer
  • Malignant Neoplasm of Pancreas
  • Liver carcinoma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: through study completion, an average of 1 year

Year 1
Accuracy is defined as the number of concordant cases between PYLARIFY PET-CT and the gold standard truth divided by the total sample size.

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Piflufolastat F18
1 of 1
Experimental Treatment

36 Total Participants · 1 Treatment Group

Primary Treatment: Piflufolastat F18 · No Placebo Group · Phase < 1

Piflufolastat F18
Drug
Experimental Group · 1 Intervention: Piflufolastat F18 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion, an average of 1 year
Closest Location: MD Anderson Cancer Center · Houston, TX
Photo of MD Anderson Cancer Center 1Photo of MD Anderson Cancer Center 2Photo of MD Anderson Cancer Center 3
2004First Recorded Clinical Trial
50 TrialsResearching Breast Cancer
521 CompletedClinical Trials

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
2,772 Previous Clinical Trials
1,795,176 Total Patients Enrolled
134 Trials studying Breast Cancer
28,169 Patients Enrolled for Breast Cancer
Lantheus Medical ImagingIndustry Sponsor
50 Previous Clinical Trials
4,331,847 Total Patients Enrolled
2 Trials studying Breast Cancer
228 Patients Enrolled for Breast Cancer
Yang Lu, MD, PHDPrincipal InvestigatorM.D. Anderson Cancer Center

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have at least one lesion on a CT, MRI, or FDG PET-CT.
You have a disease that can be measured by x-ray or CT scan, MRI, or calipers.
You have an estimated life expectancy of at least 3 months.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.